Analysts Anticipate Sarepta Therapeutics Inc (SRPT) to Post -$0.34 Earnings Per Share
Wall Street brokerages expect that Sarepta Therapeutics Inc (NASDAQ:SRPT) will report earnings of ($0.34) per share for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Sarepta Therapeutics’ earnings. The lowest EPS estimate is ($0.52) and the highest is ($0.21). Sarepta Therapeutics posted earnings of ($0.78) per share during the same quarter last year, which suggests a positive year over year growth rate of 56.4%. The company is expected to report its next earnings report on Wednesday, October 24th.
On average, analysts expect that Sarepta Therapeutics will report full-year earnings of ($1.75) per share for the current fiscal year, with EPS estimates ranging from ($2.98) to ($1.28). For the next financial year, analysts anticipate that the company will report earnings of ($1.17) per share, with EPS estimates ranging from ($2.27) to ($0.45). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.99). Sarepta Therapeutics had a negative net margin of 89.64% and a negative return on equity of 19.34%. The company had revenue of $73.53 million for the quarter, compared to the consensus estimate of $71.53 million. During the same quarter in the previous year, the business earned ($0.48) earnings per share. Sarepta Therapeutics’s revenue was up 110.0% compared to the same quarter last year.
In other Sarepta Therapeutics news, Director Richard Barry sold 75,000 shares of the firm’s stock in a transaction dated Wednesday, June 27th. The stock was sold at an average price of $130.34, for a total value of $9,775,500.00. Following the transaction, the director now directly owns 3,170,432 shares of the company’s stock, valued at $413,234,106.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Douglas S. Ingram bought 16,000 shares of the company’s stock in a transaction on Wednesday, August 15th. The stock was purchased at an average cost of $125.26 per share, for a total transaction of $2,004,160.00. Following the completion of the transaction, the chief executive officer now directly owns 399,250 shares of the company’s stock, valued at approximately $50,010,055. The disclosure for this purchase can be found here. Insiders sold 158,782 shares of company stock worth $21,237,444 over the last three months. Insiders own 7.90% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Xact Kapitalforvaltning AB boosted its position in Sarepta Therapeutics by 5.7% in the second quarter. Xact Kapitalforvaltning AB now owns 9,202 shares of the biotechnology company’s stock worth $1,216,000 after purchasing an additional 500 shares during the last quarter. Principal Financial Group Inc. boosted its position in Sarepta Therapeutics by 2.7% in the first quarter. Principal Financial Group Inc. now owns 19,946 shares of the biotechnology company’s stock worth $1,478,000 after purchasing an additional 530 shares during the last quarter. Fuller & Thaler Asset Management Inc. boosted its position in Sarepta Therapeutics by 0.5% in the second quarter. Fuller & Thaler Asset Management Inc. now owns 145,854 shares of the biotechnology company’s stock worth $19,279,000 after purchasing an additional 709 shares during the last quarter. SeaCrest Wealth Management LLC raised its stake in shares of Sarepta Therapeutics by 59.0% in the second quarter. SeaCrest Wealth Management LLC now owns 2,326 shares of the biotechnology company’s stock worth $307,000 after buying an additional 863 shares during the period. Finally, Commonwealth Equity Services LLC raised its stake in shares of Sarepta Therapeutics by 11.0% in the second quarter. Commonwealth Equity Services LLC now owns 8,989 shares of the biotechnology company’s stock worth $1,188,000 after buying an additional 892 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:SRPT traded up $2.55 on Thursday, hitting $152.76. 1,199,217 shares of the company traded hands, compared to its average volume of 810,309. Sarepta Therapeutics has a 52 week low of $42.97 and a 52 week high of $176.50. The company has a debt-to-equity ratio of 0.62, a quick ratio of 9.89 and a current ratio of 10.88.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Featured Article: Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.